miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Wang, Siao Yi ^a   Shiboski, Stephen ^a   Belair, Cassandra D ^a   Cooperberg, Matthew R ^a   Simko, Jeffrey P ^a   Stoppler, Hubert ^a   Cowan, Janet ^a   Carroll, Peter R ^a   Blelloch, Robert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 19; MICRORNA 345; MICRORNA 519C 5P; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; MIRN19 MICRORNA, HUMAN; MIRN345 MICRORNA, HUMAN; MIRN519 MICRORNA, HUMAN; MIRN520 MICRORNA, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD LEVEL; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION PROFILING; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; UPREGULATION; BLOOD; PATHOLOGY; PROSTATE TUMOR;

HUMANS; IN SITU HYBRIDIZATION; MALE; MICRORNAS; PROSTATIC NEOPLASMS;

EID: 84902438186     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098597     Document Type: Article

References (43)

1. Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302: 1685-1692.
2. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, et al. (2006) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11: 725-732.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328.
4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, et al. (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367: 203-213.
5. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, et al. (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148: 435-448.
6. Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29: 3669-3676.
7. Suardi N, Capitanio U, Chun FK, Graefen M, Perrotte P, et al. (2008) Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 113: 2068-2072.
8. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, et al. (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181: 1628-1633; discussion 1633-1624.
9. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113: 3075-3099.
10. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, et al. (2010) Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int 107: 1232-1237.
11. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
12. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170.
13. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135.
14. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, et al. (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16: 206-216.
15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518.
16. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, et al. (2009) Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4: e6229.
17. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, et al. (2011) Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71: 550-560.
18. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100: 1432-1438.
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072.
20. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101.
21. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, et al. (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30: e15.
22. Hothorn T, Hornik K, Zeileis A (2006) Unbiased recursive partitioning: A conditional inference framework. Journal of Computational and Graphical Statistics 15: 651-674.
23. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, et al. (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173: 1938-1942.
24. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
25. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
26. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
27. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, et al. (2010) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128: 608-616.
28. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, et al. (2011) Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32: 583-588.
29. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178: S14-19.
30. Klotz L (2010) Active surveillance for prostate cancer: a review. Curr Urol Rep 11: 165-171.
31. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, et al. (2007) Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 52: 1309-1322.
32. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, et al. (2011) Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 29: 2795-2800.
33. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, et al. (2004) Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64: 3087-3095.
34. Tanzer A, Stadler PF (2004) Molecular evolution of a microRNA cluster. J Mol Biol 339: 327-335.
35. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833.
36. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, et al. (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839-2849.
37. Mu P, Han YC, Betel D, Yao E, Squatrito M, et al. (2009) Genetic dissection of the miR-17,92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23: 2806-2811.
38. Dahia PL (2000) PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 7: 115-129.
39. Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, et al. (1998) Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 78: 1296-1300.
40. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, et al. (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95: 5246-5250.
41. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, et al. (2011) Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 29: 228-234.
42. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, et al. (2013) Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109: 641-650.
43. Strobl C, Boulesteix AL, Kneib T, Augustin T, Zeileis A (2008) Conditional variable importance for random forests. BMC Bioinformatics 9: 307.